Premium
P4‐187: Memantine treatment reduces the intake of concomitant antipsychotics in patients with moderate Alzheimer's disease
Author(s) -
Ihl Ralf,
Kühn Frank,
Tinschert Konstanze,
Bergtholdt Bettina,
Sternberg Kati,
Tennigkeit Frank
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.2210
Subject(s) - memantine , concomitant , medicine , visual analogue scale , dementia , activities of daily living , depression (economics) , alzheimer's disease , geriatric depression scale , anesthesia , disease , physical therapy , depressive symptoms , cognition , psychiatry , economics , macroeconomics
were also observed (Figure B and C, respectively) and were companied with increased TH, VMAT2 and dopamine levels. To confirm that Cu (atsm) exhibits its therapeutic effects via inhibition of nitrosative stress, Cu (atsm) was able to rescue toxicity and inhibit increases in nitrotyrosine levels in differentiated SH-SY5Y cells treated with 3-morpholinosydnonimine (SIN-1), a compound causes nitrosative stress. Conclusions: These findings establish the therapeutic effects of Cu (btsc) compounds in animal models and suggest that these compounds could be effective disease modifying agents for neurodegenerative diseases.